Article2007

An Open-Label Trial of Riluzole, a Glutamate Antagonist, in Children with Treatment-Resistant Obsessive-Compulsive Disorder

Lorraine Lougee · Matthew E. Hirschtritt · Susan E. Swedo

197 citations0/0 files storedJournal of Child and Adolescent Psychopharmacology

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Obsessive-Compulsive Spectrum Disorders Psychoanalysis and Psychopathology Research Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Abstract

BACKGROUND: Obsessive-compulsive disorder (OCD) in childhood is often refractory to treatment. Riluzole, a glutamate antagonist, has theoretical support as an alternative pharmacological treatment and has demonstrated possible benefit in some open-label trials in adults with OCD. METHODS: Six subjects, ages 8-16 years, were enrolled in a 12-week open-label trial of riluzole for OCD symptoms that had resisted prior treatments. OCD symptoms and adverse effects of drug were monitored. RESULTS: Four of 6 subjects had clear benefit, with reduction of more than 46% (39% overall) on Children's Yale-Brown Obsessive-Compulsive Scale, and "Much Improved" or "Very Much Improved" on the Clinical Global Impressions-Improvement scale. Two subjects had no clinically meaningful change in symptom severity by 12 weeks, but 1 subject improved thereafter. There were no adverse effects of drug sufficient to cause discontinuation or reduction of dose. All subjects elected to continue riluzole after the 12-week trial. CONCLUSIONS: Riluzole may be beneficial for treatment-resistant OCD in young subjects and seems well tolerated. A placebo-controlled trial of the drug is planned.

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 197 citations exist upstream.

References

2000FUNCTIONAL NEUROIMAGING AND THE NEUROANATOMY OF OBSESSIVE-COMPULSIVE DISORDER 2006Glutamate Transporter Gene SLC1A1 Associated With Obsessive-compulsive Disorder 2005Glutamatergic Dysfunction in OCD 2005Riluzole Augmentation in Treatment-Resistant Obsessive–Compulsive Disorder: An Open-Label Trial 2006Association Testing of the Positional and Functional Candidate Gene SLC1A1/EAAC1 in Early-Onset Obsessive-compulsive Disorder 1994Behavioral Psychotherapy for Children and Adolescents with Obsessive-Compulsive Disorder: An Open Trial of a New Protocol-Driven Treatment Package 2005Evidence-based pharmacotherapy of obsessive–compulsive disorder

Cited by

2009Anti-Brain Autoantibodies and Altered Excitatory Neurotransmitters in Obsessive–Compulsive Disorder 2012Effects of Ketamine in Treatment-Refractory Obsessive-Compulsive Disorder 2011Animal models of obsessive-compulsive disorder: Exploring pharmacology and neural substrates 2012Memantine add-on in moderate to severe obsessive-compulsive disorder: Randomized double-blind placebo-controlled study 2009Memantine Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder

Explore the map →

Papers that cite the same references — the relational fallback while embeddings are still backfilling.

Imported from OpenAlex (CC0) — nothing here is generated.